Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + Ipafricept + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Ipafricept||Fzd8-Fc|OMP-54F28||WNT Inhibitor 10||Ipafricept (OMP-54F28) is a fusion protein comprised of the ligand binding domain of the Frizzled family receptor 8 and the human immunoglobulin Fc domain, which binds Wnt and prevents downstream signaling, thereby inhibiting tumor growth (PMID: 25172549, PMID: 32694153, PMID: 31174889).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 13 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||no benefit||Carboplatin + Ipafricept + Paclitaxel||Phase Ib/II||Actionable||In a Phase Ib trial, Ipafricept (OMP-54F28) in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) was well tolerated but demonstrated bone toxicity in platinum-sensitive ovarian cancer patients, and efficacy was similar to historical data of standard of care with an overall response rate of 75.7% (28/37), a clinical benefit rate of 94.6% (35/37), a median progression-free survial of 10.3 months and an overall survival of 33 months (PMID: 31174889; NCT02092363).||31174889|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|